Literature DB >> 28464427

Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes.

Massimiliano Palazzini1, Fabio Dardi1, Alessandra Manes1, Maria L Bacchi Reggiani1, Enrico Gotti1, Andrea Rinaldi1, Alessandra Albini1, Enrico Monti1, Nazzareno Galiè1.   

Abstract

AIMS: Pulmonary hypertension (PH) is a relevant complication of left heart disease (LHD). The 2015 ESC/ERS PH guidelines report two different haemodynamic subsets of PH due to LHD (PH-LHD) based on levels of pulmonary vascular resistance (PVR) and diastolic pressure gradient (DPG): isolated post-capillary PH (Ipc-PH) and combined post- and pre-capillary PH (Cpc-PH). The objective of this study is to evaluate the prognostic value of Ipc-PH and Cpc-PH. METHODS AND
RESULTS: Data from 276 consecutive incident patients with PH-LHD were included. According to the guidelines, Ipc-PH is defined by DPG <7 mmHg and/or PVR ≤3 Wood units (WU) and Cpc-PH by DPG ≥7 mmHg and/or PVR >3 WU. Using this definition, we identified three patient groups: Ipc-PH with both normal PVR and DPG (108 patients); Cpc-PH with both increased PVR and DPG (66 patients); and an intermediate group with either increased PVR or DPG (102 patients). Survival was estimated using the Kaplan-Meier method and compared between groups using the log-rank test. Patients with Ipc-PH had better survival compared with the group of patients with Cpc-PH (P = 0.026) and the intermediate group (P = 0.025). No survival difference was detected between patients with Cpc-PH and the intermediate group (P = 0.891). Patients with normal PVR had a better survival compared with those with elevated PVR (P = 0.012); while no difference was observed according to the level of DPG (P = 0.253).
CONCLUSION: Patients with Ipc-PH have a better prognosis compared with patients with Cpc-PH and with patients with isolated increase of PVR or DPG. Pulmonary vascular resistance has a better predictive value than DPG in patients with PH-LHD.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Entities:  

Keywords:  Diastolic pressure gradient; Heart failure; Left heart disease; Pulmonary hypertension; Pulmonary vascular resistance

Mesh:

Year:  2017        PMID: 28464427     DOI: 10.1002/ejhf.860

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  20 in total

1.  Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis.

Authors:  Sergio Caravita; Céline Dewachter; Davide Soranna; Sandy Carolino D'Araujo; Amina Khaldi; Antonella Zambon; Gianfranco Parati; Antoine Bondue; Jean-Luc Vachiéry
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

Review 2.  Combined pre- and post-capillary pulmonary hypertension in left heart disease.

Authors:  M Riccardi; M Pagnesi; E Sciatti; C M Lombardi; R M Inciardi; M Metra; E Vizzardi
Journal:  Heart Fail Rev       Date:  2022-06-01       Impact factor: 4.214

3.  Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis.

Authors:  Charles-Antoine Guay; Louis-Vincent Morin-Thibault; Sebastien Bonnet; Yves Lacasse; Caroline Lambert; Jean-Christophe Lega; Steeve Provencher
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

4.  Numerical Simulation of the Effect of Pulmonary Vascular Resistance on the Hemodynamics of Reoperation After Failure of One and a Half Ventricle Repair.

Authors:  Yan Fu; Aike Qiao; Yao Yang; Xiangming Fan
Journal:  Front Physiol       Date:  2020-03-17       Impact factor: 4.566

5.  Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.

Authors:  Sergio Caravita; Andrea Faini; Sandy Carolino D'Araujo; Céline Dewachter; Laura Chomette; Antoine Bondue; Robert Naeije; Gianfranco Parati; Jean-Luc Vachiéry
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

6.  Pulmonary hypertension due to left heart disease.

Authors:  Jean-Luc Vachiéry; Ryan J Tedford; Stephan Rosenkranz; Massimiliano Palazzini; Irene Lang; Marco Guazzi; Gerry Coghlan; Irina Chazova; Teresa De Marco
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

7.  EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI).

Authors:  David G Kiely; David Levin; Paul Hassoun; David D Ivy; Pei-Ni Jone; Jumaa Bwika; Steven M Kawut; Jim Lordan; Angela Lungu; Jeremy Mazurek; Shahin Moledina; Horst Olschewski; Andrew Peacock; Goverdhan Dutt Puri; Farbod Rahaghi; Michal Schafer; Mark Schiebler; Nicholas Screaton; Merryn Tawhai; Edwin Jr Van Beek; Anton Vonk-Noordegraaf; Rebecca R Vanderpool; John Wort; Lan Zhao; Jim Wild; Jens Vogel-Claussen; Andrew J Swift
Journal:  Pulm Circ       Date:  2019-03-18       Impact factor: 3.017

8.  Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure.

Authors:  Sebastian Carballo; Philippe Musso; Nicolas Garin; Hajo Müller; Jacques Serratrice; François Mach; David Carballo; Jérôme Stirnemann
Journal:  J Clin Med       Date:  2019-10-15       Impact factor: 4.241

9.  Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Emmanouil Tampakakis; Sanjiv J Shah; Barry A Borlaug; Peter J Leary; Harnish H Patel; Wayne L Miller; Benjamin W Kelemen; Brian A Houston; Todd M Kolb; Rachel Damico; Stephen C Mathai; Edward K Kasper; Paul M Hassoun; David A Kass; Ryan J Tedford
Journal:  Circ Heart Fail       Date:  2018-04       Impact factor: 8.790

Review 10.  Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues.

Authors:  Emmanuelle Berthelot; Fabrice Bauer; Jean-Christophe Eicher; Erwan Flécher; Barnabas Gellen; Julien Guihaire; Damien Guijarro; Gérald Roul; Muriel Salvat; Christophe Tribouilloy; Florian Zores; Nicolas Lamblin; Pascal de Groote; Thibaud Damy
Journal:  ESC Heart Fail       Date:  2018-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.